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ABSTRACT
Polo-like kinases (Plk1-4) are emerging as an impor-
tant class of proteins involved in many aspects of
cell cycle regulation and response to DNA damage.
Here, we report the cloning of a fifth member of the
polo-like kinase family named Plk5. DNA and protein
sequence analyses show that Plk5 shares more
similarities with Plk2 and Plk3 than with Plk1 and
Plk4. Consistent with this observation, we show
that mouse Plk5 is a DNA damage inducible gene.
Mouse Plk5 protein localizes predominantly to the
nucleolus, and deletion of a putative nucleolus
localization signal (NoLS) within its N-terminal
moiety disrupts its nucleolar localization. Ectopic
expression of Plk5 leads to cell cycle arrest in G1,
decreased DNA synthesis, and to apoptosis, a
characteristic it shares with Plk3. Interestingly, in
contrast to mouse Plk5 gene, the sequence of
human Plk5 contains a stop codon that produces a
truncated protein lacking part of the kinase domain.
INTRODUCTION
Polo-like kinases (Plk’s) are a family of conserved serine/
threonine kinases that are highly related in their catalytic
domains. To date, there are four known Plks (Plk1, Plk2,
Plk3 and Plk4). Plks 1-3 possess two conserved ‘polo box’
motifs while Plk4 (Sak), a divergent member of the Plk
family, possesses only one of the two bipartite polo-box
motifs. The two polo boxes of Plk1, which comprise the
polo box domain (PBD), have been reported to coordinate
protein–protein interactions and subcellular localization
(1–7). Similar to Plk1, the PBDs of Plk2 and Plk3
preferentially bind phosphoserine and phosphothreonine
motifs (8–15). The Plks have been proposed to regulate
entry into mitosis, cell cycle progression, cytokinesis and
the cellular response to DNA damage deduced by their
localization to mitotic structures and phosphorylation of
speciﬁc substrates via their PBD and catalytic domains,
respectively (5,6,16–20).
The best characterized member of the Plk family is Plk1,
a key positive regulator of mitosis, meiosis and cytokinesis
(18,21). Plk1 is overexpressed in various types of cancers
and its elevated expression is associated with poor prog-
nosis. Thus, Plk1 is a validated target for anti-cancer
therapy (22–26). In recent years, a range of Plk1 molecular
targets has been identiﬁed that reveal the signaling
pathways by which Plk1 can regulate mitotic entry,
DNA damage checkpoint responses, spindle formation
and mitotic exit. Plk2 (serum-inducible kinase, Snk) and
Plk3 (FGF-inducible kinase, Fnk or Prk) are
early-response genes in quiescent mouse ﬁbroblasts that
are induced when cells are stimulated by serum (27–30).
Plk2 is also reported to be elevated in cancer cells and is a
transcriptional target of p53. Plk2 interacts with Chk1 and
Chk2 kinases and participates in S phase arrest (31). Plk2
and Plk4 appear to be involved in centriole duplication
(32–37).
Plk3 is considered to be a tumor suppressor and regu-
lator of cellular response to DNA damage and
angiogenesis (29,30,38,39). Some studies report that Plk3
expression remains relatively constant during normal cell
cycle progression (29), while others argue that Plk3 is
mainly activated during S phase entry (40) or in mitosis
(41). While Plk1 expression is downregulated upon DNA
damage (42), Plk3 expression is induced and accompanied
by an activating phosphorylation that is ATM dependent
(28–30). Activated Plk3 mediates Chk2 phosphorylation
by ATM and subsequent checkpoint activation (43), and
it participates in the onset of mitosis via inhibitory
phosphorylation of Cdc25c (44).
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in vitro and both can rescue the Saccharomyces cerevisiae
Cdc5 temperature sensitive mutant (45,46), they dif-
fer greatly in their eﬀect when transfected into mamma-
lian cells. Transfection and overexpression of Plk1
in mammalian cells results in cell transformation (47).
Overexpression of Plk3 results in cell death (48).
Plk3 has been proposed to regulate apoptosis, in part,
through the p53 pathway (28), and Plk3 knockout
mice suggest that Plk3 may be a tumor suppressor (39).
Aging mice that lack Plk3 are reported to have accelerated
tumor development, larger tumor size, and more
pronounced angiogenesis than their wild-type litter
mates (39).
Consistent with their proposed diverse roles, the
Plks are diﬀerentially expressed, exhibit distinct
subcellular localization patterns, and are subject to dif-
ferent types of post-translational modiﬁcation
(18,49,50). The mRNA and protein levels of Plk1 and
Plk2 appear to be coordinately expressed during the cell
cycle. In contrast, there is little reported concordance
regarding the expression of Plk3 mRNA and protein
levels.
Here, we report the cloning of a ﬁfth member of
the polo-like kinase family designated Plk5. Based on
its nucleotide sequence there are two apparent dis-
tinct domains within the Plk5 protein. The
amino-terminal portion has features characteristic of the
catalytic domain of a serine/threonine kinase and
shows strong homology to other polo family kinases.
The carboxy-terminal portion presumably is the regula-
tory domain, which contains the PBD and shares exten-
sive homology with the carboxy-terminal domains of the
other Plk proteins. Based on sequence similarities both
at the DNA and protein levels, Plk5 shares greater
similarity to Plk2 and Plk3 than to Plk1 and Plk4.
Consistent with this observation, we show that mouse
Plk5 gene is activated following DNA damage. The Plk5
promoter region contains several p53 binding motifs but
p53 does not appear to regulate Plk5 expression.
Interestingly, human Plk5 but not mouse Plk5 contains
a stop codon at position 807 of the nucleotide sequence
(exon 6) that leads to a truncated protein. A second
open reading frame (ORF) starts just after this stop
codon and extends through the end of the human Plk5
gene. Unlike other Plk proteins, Plk5 contains ﬁve
SQ/TQ motifs, three of which are within the PBD,
indicating that ATM, ATR or DNA-PK may
be involved in its phosphorylation and activation.
Furthermore, Plk5 mRNA levels become elevated follow-
ing introduction of DNA damage or microtubule disrup-
tion, suggesting that Plk5 is a stress induced protein that is
involved in preserving cell integrity and that responds
to a broad range of insults. Mouse Plk5 localizes
predominantly in the nucleolus and deletion of a
putative nucleolar localization signal (NoLS) within its
N-terminal moiety disrupts this subcellular localization.
Overexpression of Plk5 leads to G1 cell cycle arrest,
decreased DNA synthesis, and apoptosis, a characteristic
it shares with Plk3.
MATERIALS AND METHODS
Cloning of Plk5 cDNA, cell culture, transfection
and treatment
Plk5 cDNA (6330514A18Rik) clone MGC: 106082, which
was isolated from retina of mouse strain C57Bl\6 was
purchased from Open Biosystems (Huntsville, AL,
USA). The Plk5 ORF (1797bp) was PCR ampliﬁed and
cloned in frame with GFP protein in pEGFP-C1 vector
(Invitrogen, CA, USA). For cell culture, all cells were
cultured in Dulbecco’s modiﬁed Eagle’s medium
(DMEM) supplemented with 10% heat inactivated fetal
bovine serum (FBS; Eurobio, Les Ulis, France), 2mM
glutamine, penicillin (100Uml
 1) and streptomycin
(100mgml
 1) in a humidiﬁed atmosphere containing
5% CO2 at 37 C. Transfections were performed using
Lipofectamine 2000 (Invitrogen) following the manufac-
turer’s recommendations. For introduction of DNA
damage, cells were either treated with etoposide (40mM)
for 12h or hydroxyurea (HU) (0.5mM) for 18h.
Nocodazole was added to media at 100ng/ml for 18h.
Piﬁthrin-a (Sigma-Aldrich Inc.) was added simultaneously
with etoposide at a concentration of 10mM. Serum star-
vation was achieved by growing cells in DMEM supple-
mented with 0.1% FBS.
Nucleolar isolation
Nucleoli were prepared from NIH3T3 cell nuclei using a
method based on that ﬁrst described by Busch and
coworkers in 1963 (51). Aliquots (250ml) containing
 1 10
8 nuclei were washed three times with PBS,
resuspended in 5ml buﬀer A [10mM HEPES–KOH (pH
7.9), 1.5mM MgCl2, 10mM KCl, 0.5mM DTT], and
dounce homogenized 10 times using a tight pestle.
Dounced nuclei were centrifuged at 228g for 5min at
4 C. The nuclear pellet was resuspended in 3ml 0.25M
sucrose, 10mM MgCl2, and layered over 3ml 0.35M
sucrose, 0.5mM MgCl2, and centrifuged at 1430g for
5min at 4 C. The clean, pelleted nuclei were resuspended
in 3ml 0.35M sucrose, 0.5mM MgCl2, and sonicated for
6 10s using a microtip probe and a Misonix XL 2020
sonicator at power setting 5. The sonicate was checked
using phase contrast microscopy, ensuring that there
were no intact cells and that the nucleoli were readily
observed as dense, refractile bodies. The sonicated
sample was then layered over 3ml 0.88M sucrose,
0.5mM MgCl2 and centrifuged at 2800g for 10min at
4 C. The pellet contained the nucleoli, while the
supernatant consisted of the nucleoplasmic fraction. The
nucleoli were then washed by resuspension in 500ml
of 0.35M sucrose, 0.5mM MgCl2, followed by centri-
fugation at 2000g for 2min at 4 C.
Electrophoresis and immunoblotting
For 1D SDS/PAGE, puriﬁed nucleoli were dissolved in
1 TGN lysis buﬀer containing 50mM Tris (pH 7.5),
50mM ß-glycerophosphate, 150mM NaCl, 10%
glycerol, 1% Tween 20, 1mM NaF, 1mM sodium
orthovanadate, 1mM phenylmethylsulfonyl ﬂuoride,
2mg/ml pepstatin A, 5mg/ml leupeptin, 10mg/ml aprotinin
2932 Nucleic Acids Research, 2010,Vol.38, No. 9and 1mM DTT, and heated at 70 C for 10min. Nucleolar
proteins were then separated on 10% SDS Tris–acetate gel
and subsequently transferred onto nitrocellulose
membrane. The membranes were then incubated with
one of the following antibodies: mouse anti-GFP
(Boehringer Mannheim, Inc., Indianapolis, IN, USA),
mouse anti-NPM [B23 (FC-8791) sc-32256, Santa Cruz,
CA, USA] or a Plk5 ployclonal antibody raised
against two peptides (KEVPCLEGPIHLVAQ and
SFSGVPAQLVLSGEG) common to both mouse and
human Plk5. Bound antibody was probed using
anti-mouse HRP conjugate (1:1000 dilution) (Pierce
Chemical Co.) in PBS containing 5% milk powder and
0.05% Tween 20, and detected via chemiluminescence
with ECL (Amersham Pharmacia Biotech).
Annexin V staining for ﬂow cytometry
Apoptosis of pEGF and pEGFP-Plk5 transfected cells
was measured using the Annexin-V-Cy5.5 (Invitrogen)
and propidium iodide (PI). Brieﬂy, harvested cells were
washed in PBS and resuspended in Annexin-V binding
buﬀer (10mM HEPES, pH 7.4, 140mM NaCl, 2.5mM
CaCl2). The 2 10
5 of cells were incubated with 5ml
Annexin V-Cy5.5 and PI (1mg/ml) for 10min in the
dark at room temperature and analyzed by ﬂow
cytometry.
Cell staining and ﬂuorescence microscopy
Cells were cultured on coverslips in DMEM, 10% FBS.
Cells were washed with PBS, ﬁxed with 4%
paraformaldehyde and permeabilized for 10min at room
temperature with 0.2% Triton X-100 in PBS. After
washing, coverslips were blocked with 10% horse serum,
1% bovine serum albumin, 0.02% NaN3 in 1% PBS. Cells
were incubated with antibody against NPM [B23
(FC-8791) sc-32256, Santa Cruz] or the Plk5 antibody
for 1h at 37 C. Coverslips were washed extensively with
PBS and further incubated with 13.2nM of the appropri-
ate secondary antibody conjugated to Alexaﬂuor
568
phalloidin (Invitrogen, Eugene, OR, USA) in PBS for
30min at room temperature, washed three times with
PBS and mounted with Gelmount (Fisher Scientiﬁc,
Pittsburgh, PA, USA). Cells were visualized with the use
of a LSM 510 laser scanning confocal microscope (Zeiss,
Oberkochen, Germany).
For microscopy analysis of apoptotic morphology, ﬁxed
cells were stained with 1 mg/ml of DAPI (Invitrogen),
mounted on slides and examined under ﬂuorescence
microscope. At least 200 cells per sample were counted
in three independent experiments.
Determination of Plk5 mRNA levels by quantitative PCR
RNA was prepared according to instructions using Tri
Reagent (Molecular Research Center Inc., Cincinnati,
OH, USA). Two micrograms of total RNA was reverse
transcribed using the TaqMan Reverse Transcription
Reagent kit (Applied Biosystems, Foster City, CA,
USA). An aliquot of the cDNA was ampliﬁed for 40
cycles on an ABI Prism 7900HT Sequence Detection
System with gene-speciﬁc primers designed using the
Primer Express software (Applied Biosystems). SYBR
Green dye was used for signal detection. All analyses
were carried out in triplicate, and nontemplate controls
and dissociation curves were used to ensure speciﬁc
template ampliﬁcation. Serial dilutions of a control
cDNA were used to determine standard curves, and
curves with R
2>0.97 used to determine the mRNA
levels in individual samples. The expression level of Plk5
was calculated as a ratio of the mRNA level relative
to the mRNA level for glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) in the same cDNA. A list of
primers used for qPCR is included in the supplementary
data section (Supplementary Figure S4).
Cell cycle, BrdU incorporation and GFP content analyses
HEK293 cells were cultivated to  50% conﬂuency and
transfected with either pEGFP or pEGFP-Plk5 con-
structs. After 24h cells were trypsinized, washed twice in
PBS, and ﬁxed overnight in cold 0.25% paraformaldehyde
in PBS. Next day, cells were resuspended in 70% ethanol
and stored at 4 C until analyzed. Fixed cells were then
washed with PBS and stained with solution of 10mg/ml
propidium iodide (Molecular Probes) and 40mg/ml RNase
A (Sigma) in PBS for 30min at 37 C. Cells were analyzed
on BD LSR II ﬂow cytometer system (Becton Dickinson,
Franklin Lakes, NJ, USA).
For BrdU incorporation analysis, 30min prior to
harvest 1mg/ml of BrdU was added to culture medium.
Following ﬁxation procedure described for cell cycle
analysis (2% paraformaldehyde was used), cells were
washed with PBS. DNA denaturation was performed
using 2M HCl with 0.5% Triton X-100 at 37 C for 1h.
Following 10min neutralization in 0.1M NaBO4 cells were
incubated with BrdU-speciﬁc antibody (Calbiochem,
EMD, Darmstadt, Germany) in 1% BSA in PBS over-
night at 4 C on shaking platform. Cells were washed
once with PBS and incubated 1h at room temperature
with secondary antibody conjugated with Alexa Fluor
680 (Invitrogen). Thirty minutes prior to ﬂow cytometric
analysis, PI (10mg/ml) and RNAse (40 mg/ml) were added
and cells were incubated in dark at 37 C.
The fraction of GFP positive cells was determined by
ﬂow cytometry using similar ﬁxation protocol similar to
that for cell cycle analysis. At least 10
4 cells per sample in
three independent experiments were analyzed.
RESULTS
Cloning of Plk5 and sequence comparison to other
members of the Plk family
A database search [ENSEMBL (www.ensembl.org)] for
proteins with a PBD was initiated after a western blot
for Plk3 using commercially available antibodies
unexpectedly detected a band of approximately correct
size in cell extracts of mouse embryo ﬁbroblasts derived
from Plk3 knockout mice (to be described elsewhere). The
search identiﬁed an unannotated murine gene on
Chromosome 10 [RIKEN cDNA 6330514A18 gene
(Marker Symbol; Acc: MGI: 3026984)] with an apparent
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protein that was designated Plk5. The RIKEN cDNA
6330514A18 was ﬁrst identiﬁed as part of a retinal
transcriptome screen and described as a sequence weakly
similar to polo-like kinase 2 from Xenopus laevis (52,53).
The Plk5 polo box has 37% amino acid similarity to the
duplicated polo boxes of Plk3 (Supplementary Figure S1).
Although Plk5 is conserved among vertebrate species, the
degree of peptide sequence homology between mouse and
human (57%) is considerably lower than interspeciﬁc
mouse to human homologies of other Plks (95%, 96%,
79% and 78% for Plk1, Plk2, Plk3 and Plk4, respectively).
The Plk5 gene sequence from diﬀerent organisms seems to
cluster depending on phylogenetic distance (Figure 1A).
The most striking diﬀerence between human, chimpanzee
and orangutan Plk5 on the one hand, and mouse, chicken
or Xenopus on the other is that the former contain a
nonsense codon in the 50 third of the gene in exon 6
resulting in a truncation in the N-terminal part of the
protein (Figure 1B). Translation of the immediately
adjacent ORF encodes a peptide that contains the PBD
but lacks two thirds of the kinase domain (218 amino
acids) including the ATP binding site. To validate the
truncating stop codon in hPlk5, the region containing
this nonsense codon was ampliﬁed by RT–PCR and the
DNA sequence from multiple cell lines of tumor and
nontumor origin was determined (Figure 1C). The
murine sequence was determined independently and used
as a reference. The Plk5 DNA sequence from all ﬁve
human cell lines contained the TAG stop codon whereas
the mouse sequence did not (Figure 1C).
The mPlk5 protein sequence diﬀers from that of the
other Plks in that it contains three putative NoLS local-
ization sequences and ﬁve SQ/TQ motifs (Figure 1B).
Unlike the promoter region of the other Plks, the
promoter region of both human and mouse Plk5
sequences contains p53 consensus response elements and
putative CpG methylation islands.
Another diﬀerence between Plk5 and the other polo-like
kinases is that Plk5 is not induced following serum stim-
ulation. NIH 3T3 cells were rendered quiescent by serum
deprivation and 48h later, cells were stimulated to enter S
phase and proliferate by addition of serum. The levels of
mRNA for Plk3 and Plk5 were compared. As expected,
the levels of Plk3 mRNA increased up to 10-fold, consis-
tent with previous ﬁndings (27). The level of Plk5 mRNA,
however, remained unchanged indicating that Plk5 is not
serum inducible (Supplementary Figure S2).
Both mouse and human Plk5 proteins are expressed
in vivo
To test whether human and mouse Plk5 proteins were
expressed in vivo, a polyclonal antibody was raised
against two small peptides conserved in both human and
mouse Plk5. In vivo expression of both proteins was tested
by western blot, immunoﬂuorescence and immunopre-
cipitation followed by mass spectrometry identiﬁcation.
Both mouse and human Plk5 proteins were detected
by western blot at the expected sizes (Figure 2A and B).
The mouse Plk5 protein was detected around the predicted
size of 72kDa and the identity of the protein was con-
ﬁrmed by immunoprecipitation followed by mass
spectrometry (Supplementary Figure S3). The mouse
Plk5 was also detected by immunoﬂuorescence which
shows that mPlk5 is localized in discrete foci in vivo
(Figure 2C). The human Plk5 splice variant was also
detected by western blot as a doublet at about 34kDa,
roughly equal to the computed molecular weight. The
identity of the human Plk5 protein was conﬁrmed by
shRNA-mediated depletion, followed by western blot,
showing that the detected band corresponds to the
human Plk5 protein (Figure 2D). To test whether the
human Plk5 protein is functional in vivo, we used a
shRNA to deplete Plk5 and analyzed its eﬀect on cell
cycle distribution in the presence and absence of DNA
damage. While, the cell cycle proﬁle remained mostly
intact in the absence of DNA damage, cells depleted of
Plk5 show a defect in the G2/M checkpoint following
treatment with the DNA damaging agent, etoposide
(Figure 2E). This result indicates that the truncated
human Plk5 is not only expressed in vivo, but functional
as well.
Ectopic expression of Plk5 induces a G1 arrest and
subsequent apoptotic cell death
Overexpression of Plk1 induces mitotic abnormalities (47),
and has the capacity to transform NIH 3T3 cells (47).
Overexpression of Plk3 inhibits proliferation, and
induces cell death (48). We have now assessed the eﬀects
of Plk5 overexpression on cellular proliferation and cell
cycle progression. Transfection of mouse Plk5 cDNA into
HEK293 or NIH3T3 cells produced no colonies in either
cell line that stably overexpress the protein, suggesting
that overexpression of Plk5 is either generally cytostatic
or cytotoxic. Growth curves of cells following transfection
with either a pEGFP-mPlk5 construct or a pEGFP vector
expressing GFP protein alone showed that ectopic expres-
sion of mPlk5 in both cell lines inhibited cellular prolifer-
ation while expression of GFP alone had no profound
eﬀect (Figure 3A). To determine whether cells transfected
with Plk5 arrest randomly throughout the cell cycle or
accumulate preferentially at one or more cell cycle
phases, HEK293 cells were transfected with
pEGFP-mPlk5 or pEGFP alone and subjected to ﬂow
cytometry to determine cell cycle distribution. As shown
in Figure 3B, the cells accumulated in the G1 phase of the
cell cycle within 24h after transfection with mPlk5.
Nontransfected cells or those transfected with GFP
alone exhibited a normal cell cycle proﬁle, but by 48h,
very few cells transfected with GFP-mPlk5 remained on
the culture plate (Figure 3A) indicating that cells
overexpressing mPlk5 undergo cell death. Similarly, cells
transfected with pEGFP-mPlk5 accumulated in G1
(Figure 3B) and failed to enter S phase as conﬁrmed by
reduced staining with BrdU (Figure 3C). The cell cycle
distribution of cells transfected with pEGFP alone was
unaltered and similar to that of untransfected cells with
normal levels of BrdU incorporation (Figure 3B and C).
2934 Nucleic Acids Research, 2010,Vol.38, No. 9Since cells that overexpress Plk5 appear to undergo
rapid cell death, we asked whether cell death was due to
apoptosis. To this end, cells were transiently transfected
with the pEGFP-mPlk5 or the pEGFP control plasmid.
Forty-eight hours after transfection, cells were stained for
Annexin V, an early marker of apoptosis, and analyzed by
ﬂow cytometry. Transfection with pEGFP alone resulted
in background levels of Annexin V staining in EGFP-
positive cells. Transfection of cells with pEGFP-mPlk5,
however, resulted in a dramatic increase in staining with
Annexin V (Figure 3D). Consistent with the Annexin V
staining, there was a signiﬁcant increase in the number of
Figure 1. Structural organization of mouse and human Plk5. (A) A rooted tree was constructed using PHYLIP (70) showing one model of evo-
lutionary descent. (B) Shared domains between mPlk5, hPlk5 and the other Plks. NoLS indicates the nucleolus localization signal. (C) Plk5 DNA
sequence from diﬀerent human cell lines of cancer and noncancer origin showing the presence of the nonsense codon in exon 6. The cell lines include:
HEK-293 (Human embryonic kidney cell line), FHC (normal human fetal colon cell line), DLD-1 (human colon carcinoma), MCF-7 (breast cancer
cell line) and MDA-231 (breast cancer cell line). The mouse Plk5 sequence is also shown for comparison.



































Figure 2. Human and mouse Plk5 proteins are both expressed in cultured cells. Western blot showing that mouse Plk5 (A) and human Plk5 (B)
proteins are detected in lysates from NIH3T3 and HEK-293 cells, respectively, using a Plk5 polyclonal antibody. (C) Immunoﬂuorescence detection
of endogenous mPlk5 in discrete foci (arrows) in NIH3T3 cells. (D) A shRNA that targets hPlk5 mRNA was able to deplete Plk5 protein from
HEK-293 cells. (E) HEK-293 cells transiently transfected with vector expressing both shRNA against Plk5 and GFP were analyzed by ﬂow
cytometry. The cell cycle distribution of GFP-positive cells is shown in left top corner of each panel. Depletion of hPlk5 from HEK-293cells
leads to loss of G2/M checkpoint in response to treatment with the DNA damaging agent, etoposide (lower panel, right) compared to nondepleted
cells (lower panel, left).
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Figure 3. Ectopic expression of murine Plk5 induces G1 arrest and cell death by apoptosis. (A) Growth curves of cells transfected by either a pEGFP
plasmid control or a pEGFP-mPlk5 construct. (B) Cell cycle proﬁle of cells transfected with either pEGFP or pEGFP-mPlk5 showing G1
arrest in the Plk5 transfected cells. (C) BrdU staining of cells transfected by either pEGFP or pEGFP-mPlk5 conﬁrms the G1 arrest in the Plk5
transfected cells (upper panel, right) compared to GFP transfected cells (upper panel, left). No major change is seen in GFP negative cells
(lower panel). (D) Annexin staining of the transfected cells showing increased apoptosis in pEGFP-mPlk5 transfected cells and (E) Quantitave
analysis of nuclei with apoptotic morphology as a result of mPlk5 expression conﬁrming the Annexin V staining. Asterisk denotes statistical
diﬀerence P<0.05.
Nucleic Acids Research,2010, Vol.38, No. 9 2937cells transfected with pEGFP-mPlk5, but not with
pEGFP, that had condensed and/or fragmented nuclei,
an independent marker of apoptosis (Figure 3E). These
data support the observation that ectopic expression of
mPlk5 inhibits cellular proliferation by arresting cells in
G1 and inducing apoptosis.
Plk5 localizes predominantly to the nucleolus and its
nucleolar localization is not fully required for
induction of cell death
Subcellular localization of endogenous Plk5 was deter-
mined by immunohistochemistry using a polyclonal Plk5
antibody (Figure 2C) or by ectopically expressing
Plk5 following transfection of cells with GFP-Plk5. Plk5
localized predominantly within discrete foci in the nucleus
(Figure 4A), and localization to the nucleolus was sup-
ported by co-localization with nucleophosmin (NPM), a
nucleolar marker (Figure 4B). Nucleolar localization was
further conﬁrmed by fractionating isolated nuclei for
nucleolar enrichment, and probing for either GFP-Plk5
or NPM. As shown in Figure 4C, Plk5 and NPM
were both greatly enriched in the nucleolar fraction.
Sequence analysis of the mPlk5 protein revealed three
separate nucleolar localization signal (NoLS) motifs in
the N-terminal domain of mPlk5 (missing in hPlk5).
Deletion analysis of each of the NoLS motifs individually
revealed that the absence of only one NoLS led to loss of
nucleolar localization (Figure 4D). Nucleolar localization
of Plk5 is not fully required for inducing cell death by
apoptosis. The nucleolar mutant, although much less
toxic to the cells than wild type, is still able to induce
more apoptosis compared to GFP control as indicated
by the percentage of Annexin V positive cells
(Supplementary Figure S5).
Plk5 expression is induced in response to multiple
stressors
Plk5 has more characteristics in common with Plk2 and
Plk3 than with Plk1 and Plk4. We therefore asked whether
expression of Plk5 like Plk2 and Plk3, is inducible by
DNA damage. Murine NIH3T3 cells were treated with
DNA damaging agents and the levels of Plk5 mRNA tran-
script were assessed by qPCR. The levels of Plk5 mRNA
increased markedly following DNA damage by treatment
Figure 4. mPlk5 localizes to the nucleolus. (A) GFP-mPlk5 localizes to discrete foci. (B) GFP-mPlk5 co-localization with endogenous NPM in the
nucleolus. (C) Enrichment for mPlk5 in the nucleolar fraction. (D) Loss of nucleolar localization in the NoLS mutant.
2938 Nucleic Acids Research, 2010,Vol.38, No. 9with etoposide, a topoisomerase II inhibitor that induces
DNA double strand breaks (Figure 5A and B).
Nocodazole, which interferes with microtubule polymer-
ization and activates the spindle checkpoint, also induced
Plk5 expression, as did inhibition of replication by HU.
Interestingly, serum starvation also elevated levels of Plk5
mRNA (Figure 5A), but this increase was reversed upon
addition of serum (data not shown). This ﬁnding
distinguishes Plk5 from Plk3 which is serum inducible.
The broad range of reagents that can induce Plk5 expres-
sion indicates that Plk5 is a stress inducible gene with
potential involvement in a variety of processes designed
to protect cells from a wide range of insults.
Induction of Plk5 in response to DNA damage is not
dependent on p53
Unlike other Plk genes, mouse and human Plk5 contains
p53 response elements (Figure 6A). To determine whether
p53 plays a functional role in Plk5 transcriptional activa-
tion, NIH 3T3 cells were treated with piﬁthrin-a,a
chemical inhibitor of p53-dependent transcription, and
tested for Plk5 response to DNA damage induced by
etoposide. The loss of p53 activity was conﬁrmed by the
lack of p21 expression following etoposide treatment
(Figure 6B). NIH3T3 cells were left untreated, treated
with piﬁthrin-a, etoposide or etoposide plus piﬁthrin-a
and the mRNA level measured by qPCR. As shown in
Figure 6C, the levels of Plk5 mRNA did not drop in the
etoposide treated cells in the presence of piﬁthrin-a but
rather showed a slight but reproducible increase. These
results indicate that Plk5 induction in response to DNA
damage is not p53-dependent.
DISCUSSION
The Plk family comprises a group of serine/threonine
kinases (54) that can also bind motifs containing a
phosphoserine or phosphothreoine residue (8–15). In the
case of Plk3, a priming phosphorylation of Chk2 facili-
tates subsequent phosphorylation by ATM to activate the
Chk2 kinase (38). As a family, the Plks contribute to a
broad spectrum of cellular roles, many of which are pre-
sumably coordinated into the functions of a single polo
kinase in ﬂies and lower eukaryotes (5,6,16–20).
Drosophila and Caenorhabditis elegans have a single Polo
kinase, whereas mammals have four reported Plks
(designated Plk1 through Plk4) that encompass roles as
diverse as participation in centrosome dynamics, the
intra-S-phase checkpoint, spindle formation, cytokinesis,
G2/M checkpoints of the cell cycle and the DNA damage
response (16–20). Homozygous disruption of Plk1 or Plk4
in mice is fetal lethal (55,36), whereas mice lacking Plk2
and Plk3 are viable (56,39).
When cell extracts from mice in which the promoter and
ﬁrst six exons had been removed by targeted homologous
recombination produced a band of predicted size for
Plk3 in western blots using a commercial Plk3 antibody,
we searched available databases for other sequences
that potentially might cross-react. We identiﬁed an
unannotated sequence, which has been designated
6330514A18RIK (52,53). The protein named Plk5
contains two polo boxes and has additional similarity to
the known polo-like kinases. The cDNA sequences for
mouse and human Plk5 were cloned by RT–PCR and
recombinant protein was produced in Escherichia coli.
Analysis of protein and DNA sequences suggested that
Plk5 is more similar to Plk2 and Plk3 than to the Plk1
and Plk4 kinases. Functionally, however, mouse Plk5
appears to have unique characteristics. The known
Plks are reported to promote spindle formation at G2/
M, to activate the anaphase promoting complex (APC)
as cells transit through mitosis, to participate in the
process of cytokinesis, and to participate in DNA
damage checkpoint signaling cascade in G2/M (16–20).
The Plk1 kinase has numerous mitotic functions including







































































Figure 5. Plk5 expression is induced following diﬀerent stress stimuli. (A) Murine NIH 3T3 cells were either left untreated (control) or treated for
18h with the DNA damaging agents etoposide (Etop) or HU, the spindle disassembly agent, nocodazole (Noc) or were serum starved (SS).
(B) Human HEK293 cells were either left untreated (control) or treated with DNA damaging agent etoposide or doxorubicin for 6 or 24h.
The Plk5 mRNA level was measured by qPCR in both cases.
Nucleic Acids Research,2010, Vol.38, No. 9 2939recruitment of g-tubulin to centrosomes (57). The Plk4
kinase, also designated Sak, is required for the destruction
of cyclin B by the APC complex and for exit from mitosis
in the postgastrula embryo (36). The Plk2 and Plk3 genes
are expressed as immediate-early transcripts and their
function has been mainly associated with mitosis and
DNA damage response (28–31).
The mouse Plk5 kinase appears to reside in the
nucleolus. When GFP-tagged Plk5 is introduced into
cultured cells, it quickly localizes to the nucleolus and
subsequently causes the cells to undergo apoptosis.
Nucleolar localization is not fully required for
Plk5-induced apoptosis since a deletion mutant lacking a
functional NoLS also induces cell death although much
less eﬃciently. The endogenous Plk5 can also be visualized
within the nucleolus with the Plk5 antibody. The Plk5
protein has three nucleolar localization motifs at its
amino end, only one of which appears to be required for
nucleolar localization. These data suggest that in mice
Plk5 is either sequestered within nucleoli and participates
in ribosome biogenesis or other nucleolar function, or that
it remains in nucleoli until cells are stressed by DNA
damage at which time it is released to participate in the
cellular response to such damage. Indeed, recent reports
indicate that the nucleolus also functions in the regulation
of DNA-damage response, primarily through sequestra-
tion of regulators, such as p53, MDM2, CDC14b, pRB,
pRB2, E2F4, p107 and p14ARF (58–65). However, we
were unable to see any change in Plk5 localization follow-
ing any form of stress to the cell. Consistent with its
A
B C
Figure 6. Plk5 transcriptional activation in response to DNA damage is not p53-dependent. (A) p53 consensus binding sites in Plk5 promoter,
(B) mPlk5 mRNA expression levels measured by qPCR following etoposide and piﬁthrin treatment of NIH 3T3 cells for 18h. (C) Expression of p21
protein in lysates from cells either nontreated (1), treated with piﬁthrin (2), etoposide alone (3) or piﬁthrin and etoposide (4) was analyzed by western
blot.
2940 Nucleic Acids Research, 2010,Vol.38, No. 9putative involvement in DNA damage response, the Plk5
gene contains three p53 regulatory elements in the
promoter region. The gene, however, appears to be
responsive to DNA damage, but not in a p53-dependent
manner. The level of Plk5 mRNA is elevated following
treatment with etoposide, a topoisomerase II inhibitor
which causes double strand DNA breaks, as well as
nocodazol, a mitotic inhibitor. It is also elevated after
treatment with HU, which causes replication forks to
stall. Treatment of cells with piﬁthrin, an inhibitor of
p53 function, prevents an increase in p21 protein but has
little eﬀect on the induction of Plk5 mRNA in cells treated
with etoposide or HU. These data suggest that mouse Plk5
is inducible following DNA damage but that despite the
presence of p53 response elements within the Plk5
promoter; its induction is not dependent on p53.
This report has emphasized mouse Plk5 since the gene
encoding the human protein has a mutation in exon 6 that
introduces a stop codon into the Plk5 reading frame,
terminating the protein within the putative kinase
domain. The ensuing ORF encodes a protein that
retains the remainder of the kinase domain and the polo
box domain. This short protein is expressed in vivo and its
expression is induced in response to stress and its
overexpression induces cell death although at lesser
extent compared to full-length mouse Plk5. Depletion of
the hPlk5 leads to loss of the G2/M checkpoint in
response to DNA damage indicating that this truncated
form of Plk5 still retains some Plk5 functions.
The mouse and human Plk5 genes are quite similar in
sequence, but their function appears to have diverged
within recent evolutionary times. The truncating stop
codon is found in the great apes and apparently
occurred at the time of or just before the divergence of
the orangutan from the other primates, including Homo
sapiens. Whether retention of the inactivating stop codon
was maintained due to selective pressure or absence of
selective advantage is unclear, but it represents an
apparent example of recent evolutionary divergence.
Loss of a functional gene and gene product in humans is
not unique to Plk5. In some cases, evolutionary loss of a
gene in humans can predispose to disease. Loss of the gene
encoding L-gulono-gamma-lactone oxidase that is
involved in synthesis to ascorbic acid in most eukaryotes
renders primates prone to scurvy in the absence of dietary
vitamin C (66). Similarly, primates, including humans,
have lost the gene encoding urate oxidase predisposing
them to hyperuricemia, gout and renal stones (67). The
human threonine dehydrogenase gene also contains an
inactivating nonsense mutation (68) which may account
for observed diﬀerences in metabolism and growth
kinetics of mouse and human embryonic stem cells (69).
One unusual aspect of human Plk5 is that the inactivating
stop codon is immediately followed by a methionine and a
sizable ORF that may not only retain some of the intact
Plk5 functions, but has the potential for serving a cellular
function diﬀerent than that of Plk5. It is unclear whether
loss of Plk5 has a selective advantage in humans and other
hominids, but the abbreviated peptides encoded by
the hominid Plk5 gene, and their potentially altered
function, may have been suﬃcient to confer the necessary
selective advantage for the mutated Plk5 to persist.
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